Tofacitinib Does Not Impair Sperm Quality in Men With Ulcerative Colitis
Lay Summary We demonstrate that tofacitinib does not adversely affect semen quality or sex hormones in male patients. These first postmarketing data for tofacitinib and semen quality are reassuring. Our study raises no safety concerns, though larger studies are needed to confirm our findings.
Authors
- Anne Grosen (ORCID: https://orcid.org/0000-0001-5158-4112)
- Stephen B. Hanauer (ORCID: https://orcid.org/0000-0002-3268-932X)
- Emanuelle Bellaguarda
- Ingela Liljeqvist-Soltic
- Jens Kelsen (ORCID: https://orcid.org/0000-0002-7133-0256)
- Anne‐Bine Skytte (ORCID: https://orcid.org/0000-0002-0067-9557)
Institutions
- Northwestern University (US)
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1093/ibd/izae195
- Citations
- 1
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.54